Kyowa Hakko Bio Co., Ltd.April 11, 2022

FDA 483 - Kyowa Hakko Bio Co., Ltd. - April 11, 2022

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Kyowa Hakko Bio Co., Ltd.

Record Details

Kyowa Hakko Bio Co., Ltd. in Hofu-city, Japan, an API manufacturer, received a Form 483 with five observations. The inspection revealed significant deficiencies in the quality control unit's adherence to procedures, inadequate evaluation of change control impacts on API quality, insufficient water monitoring specifications, and inadequate laboratory and production system controls. These issues indicate a systemic lack of robust quality management and control.

Company: Kyowa Hakko Bio Co., Ltd.
Inspection Date: April 11, 2022
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Teresa I. Navas

Open in Dashboard

ID · 911e3418-d0c9-42ad-a767-662ef0cf7b3d